Diligence memo · auto-generated · as of July 2, 2026
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Fulcrum Therapeutics, Inc. operates in Biotechnology, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Fulcrum Therapeutics, Inc. has raised $183M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $80M on 2018-08-24.
Most recent recorded round closed around 2020-06-09.
Valuation (modeled)modeled
Provath models Fulcrum Therapeutics, Inc. at approximately $2.8B (range $212M–$7.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.44× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Within the normal band (144% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 6.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 96% of Biotechnology peers (4293 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.